Dr. Chana L. Glasser
Claim this profileNYU Winthrop Hospital
Studies Neuroblastoma
Studies Cancer
29 reported clinical trials
81 drugs studied
About Chana L. Glasser
Education:
- Earned an MD from the University of Medicine & Dentistry of New Jersey in 2009.
- Completed a Residency in Pediatrics at Mount Sinai School of Medicine in 2012.
- Finished a Fellowship in Pediatric Hematology/Oncology at New York-Presbyterian Hospital in 2015.
Experience:
- Serves as Clinical Associate Professor in the Department of Pediatrics at NYU Long Island School of Medicine.
- Holds the position of Division Chief of Pediatric Hematology and Oncology at NYU Langone Hospital – Long Island.
- Acts as Course Co-Director for the Hematology-Oncology System at NYU Long Island School of Medicine.
- Board Certified in Pediatric Hematology-Oncology (2017) and Pediatrics (2012) by the American Board of Pediatrics.
Area of expertise
1Neuroblastoma
MYC positive
Stage IV
MYC negative
2Cancer
Stage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Chana L. Glasser is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Chana L. Glasser
Clinical Trial Related8 years of experience running clinical trials · Led 29 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Chana L. Glasser has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Methotrexate
- Radiation Therapy
Breakdown of trials Chana L. Glasser has run
Neuroblastoma
Cancer
Brain Tumor
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chana L. Glasser specialize in?
Chana L. Glasser focuses on Neuroblastoma and Cancer. In particular, much of their work with Neuroblastoma has involved MYC positive patients, or patients who are Stage IV.
Is Chana L. Glasser currently recruiting for clinical trials?
Yes, Chana L. Glasser is currently recruiting for 13 clinical trials in Mineola New York. If you're interested in participating, you should apply.
Are there any treatments that Chana L. Glasser has studied deeply?
Yes, Chana L. Glasser has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Chana L. Glasser?
Apply for one of the trials that Chana L. Glasser is conducting.
What is the office address of Chana L. Glasser?
The office of Chana L. Glasser is located at: NYU Winthrop Hospital, Mineola, New York 11501 United States. This is the address for their practice at the NYU Winthrop Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.